awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q33424116-52A135BF-03F5-455E-94BA-F98DACC97FB0
Q33424116-52A135BF-03F5-455E-94BA-F98DACC97FB0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33424116-52A135BF-03F5-455E-94BA-F98DACC97FB0
Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
P2860
Q33424116-52A135BF-03F5-455E-94BA-F98DACC97FB0
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33424116-52A135BF-03F5-455E-94BA-F98DACC97FB0
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
65bb2dda364452587d63053d7b918f1a5fe2cf5f
P2860
Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?